Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer

NCT00130520 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT00130520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00130520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
May 31, 2010
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms